Molecular addresses of tumors: Selection by in vivo phage display

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 3, 2006, Pages 177-181

  Li, Xiao Bo ^a,b   Schluesener, Hermann J ^b   Xu, Shun Qing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angiogenesis; Phage display; Tumor antigen; Tumor therapy

Indexed keywords

PEPTIDE; PEPTIDE LIBRARY; TUMOR ANTIGEN; TUMOR MARKER;

ANGIOGENESIS; BLOOD VESSEL; CANCER STAGING; CANCER THERAPY; IN VIVO STUDY; LYMPH VESSEL; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; REVIEW; STRUCTURE ANALYSIS; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENIC PROTEINS; ANIMALS; ANTIGENS, NEOPLASM; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY;

EID: 33747467583     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0026-y     Document Type: Review

References (58)

1. An P., Lei H., Zhang J., Song S., He L., Jin G., Liu X., Wu J., Meng L., Liu M. and Shou C. (2004): Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int. J. Cancer, 111, 165-173.
2. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H. M., Bredesen D. E., Pasqualini R. and Ruoslahti E. (2002): Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA, 99, 1527-1531.
3. Arap W., Pasqualini R. and Ruoslahti E. (1998): Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380.
4. Asai T., Fukatsu H., Kuromi K., Ogino K., Tanaka M., Oku N. and Taki T. (2002): Isolation of a novel peptide homing to tumor-derived neovasculature that suppresses tumor growth. Biol. Pharm. Bull., 25, 904-906.
5. Asai T., Nagatsuka M., Kuromi K., Yamakawa S., Kurohane K., Ogino K., Tanaka M., Taki T. and Oku N. (2002): Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett., 510, 206-210.
6. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A. and Oku N. (2002): Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett., 520, 167-170.
7. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G. and Mazie J. C. (2000): Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J., 19, 1525-1533.
8. Boldicke T., Tesar M., Griesel C., Rohde M., Grone H. J., Waltenberger J., Kollet O., Lapidot T., Yayon A. and Weich H. (2001): Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem Cells, 19, 24-36.
9. Bockmann M., Drosten M. and Putzer B. M. (2004): Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J. Gene Med., 7, 179-188.
10. Bosserhoff A. K., Stoll R., Sleeman J. P., Bataille F., Buettner R. and Holak T. A. (2003): Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab. Invest., 83, 1583-1594.
11. Burton D. R. and Barbas C. F. 3rd. (1994): Human antibodies from combinatorial libraries. Adv. Immunol., 57, 191-280.
12. Cao J., Zhao P., Miao X. H., Zhao L. J., Xue L. J. and Qi Zt Z. (2003): Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81. Cell Res., 13, 473-479.
13. Carnemolla B., Neri D., Castellani P., Leprini A., Neri G., Pini A., Winter G. and Zardi L. (1996): Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer, 68, 397-405.
14. Curnis F., Gasparri A., Sacchi A., Longhi R. and Corti A. (2004): Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res., 64, 565-571.
15. De Berardinis P., Sartorius R., Caivano A., Mascolo D., Domingo G. J., Del Pozzo G., Gaubin M., Perham R. N., Piatier-Tonneau D. and Guardiola J. (2003): Use of fusion proteins and procaryotic display systems for delivery of HIV-1 antigens: development of novel vaccines for HIV-1 infection. Curr. HIV Res., 1, 441-446.
16. Ding B. S., Zhou Y. J., Chen X. Y., Zhang J., Zhang P. X., Sun Z. Y., Tan X. Y. and Liu J. N. (2003): Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation, 108, 2892-2898.
17. El-Mousawi M., Tchistiakova L., Yurchenko L., Pietrzyn-ski G., Moreno M., Stanimirovic D., Ahmad D. and Alakhov V. (2003): A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. Biol. Chem., 278, 46681-46691.
18. Healy J. M., Murayama O., Maeda T., Yoshino K., Sekiguchi K. and Kikuchi M. (1995): Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry, 34, 3948-3955.
19. Hellstrom I., Garrigues H. J., Garrigues U. and Hellstrom K. E. (1990): Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le (y)-related cell surface antigens. Cancer Res., 50, 2183-2190.
20. Hetian L., Ping A., Shumei S., Xiaoying L., Luowen H., Jian W., Lin M., Meisheng L., Junshan Y. and Chengchao S. (2002): A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem., 277, 43137-43142.
21. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T. and Alitalo K. (2002): Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst., 94, 819-825.
22. Hoffman J. A., Giraudo E., Singh M., Zhang L., Inoue M., Porkka K., Hanahan D., Ruoslahti E. (2003): Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 4, 383-391.
23. Ho I. A., Lam P. Y. and Hui K. M. (2004): Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum. Gene Ther., 15, 719-732.
24. Jacobson B. S., Stolz D. B. and Schnitzer J. E. (1996): Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat. Med., 2, 482-484.
25. Jackson D. G., Prevo R., Clasper S. and Banerji S. (2001): LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol., 22, 317-321.
26. Joyce J. A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E. and Hanahan D. (2003): Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4, 393-403.
27. Kelly K. A., Allport J. R., Tsourkas A., Shinde-Patil V. R., Josephson L. and Weissleder R. (2005): Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res., 96, 327-336
28. Kohler G. and Milstein C. (1975): Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
29. Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O. P., Heikkila P., Kantor C., Gahmberg C. G., Salo T., Konttinen Y.T., Sorsa T., Ruoslahti E. and Pasqualini R. (1999): Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 17, 768-774.
30. Koivunen E., Wang B. and Ruoslahti E. (1995): Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology, 13, 265-270.
31. Koolpe M., Dail M. and Pasquale E. B. (2002): An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem., 277, 46974-46979.
32. Laakkonen P., Akerman M. E., Biliran H., Yang M., Ferrer F., Karpanen T., Hoffman R. M. and Ruoslahti E. (2004): Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc.Natl. Acad. Sci. USA, 101, 9381-9386.
33. Laakkonen P., Porkka K., Hoffman J. A. and Ruoslahti E. (2002): A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med., 8, 751-755.
34. Landon L. A. and Deutscher S. L. (2003): Combinatorial discovery of tumor targeting peptides using phage display. J. Cell Biochem., 90, 509-517.
35. Lei H., Shou C., Wu J., Liu X., He L., Liu M., Guo Q. and Jiang B. (2002): Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1. Zhonghua Yi Xue Za Zhi, 82, 1342-1345.
36. Mandriota S. J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D. G., Orci L., Alitalo K., Christofori G. and Pepper M. S. (2001): Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J., 20, 672-682.
37. Maruta F., Parker A. L., Fisher K. D., Murray P. G., Kerr D. J. and Seymour L. W. (2003): Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J. Drug Target, 11, 53-59.
38. Mutuberria R., Satijn S., Huijbers A., Van Der Linden E., Lichtenbeld H., Chames P., Arends J. W. and Hoogenboom H. R. (2004): Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J. Immunol. Methods, 287, 31-47.
39. Nissim A., Hoogenboom H. R., Tomlinson I. M., Flynn G., Midgley C., Lane D. and Winter G. (1994): Antibody fragments from a "single pot" phage display library as immuno-chemical reagents. EMBO J., 13, 692-698.
40. O'Brien P. M., Aitken R., O'Neil B. W., Campo M. S. (1999): Generation of native bovine mAbs by phage display. Proc. Natl. Acad. Sci. USA, 96, 640-645.
41. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., Ogino K., Tanaka M., Ishikawa D., Tsukada H., Momose M., Nakayama J. and Taki T. (2002): Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene, 21, 2662-2669.
42. Pan B., Li B., Russell S. J., Tom J. Y., Cochran A. G. and Fairbrother W. J. (2002): Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. J. Mol. Biol., 316, 769-787.
43. Pasqualini R. and Ruoslahti E. (1996): Organ targeting in vivo using phage display peptide libraries. Nature, 380, 364-366.
44. Pasqualini R., Arap W. and McDonald D. M. (2002): Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med., 8, 563-571.
45. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T. M., Corti A. and Ponzoni M. (2003): Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res., 63, 7400-7409.
46. Pepper M. S. (2001): Lymphangiogenesis and tumor metastasis: myth or reality? Clin. Cancer Res., 7, 462-468.
47. Porkka K., Laakkonen P., Hoffman J. A., Bernasconi M. and Ruoslahti E. (2002): A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA, 99, 7444-7449.
48. Rafii S., Avecilla S. T. and Jin D. K. (2003): Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell, 4, 331-333.
49. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R. and Ruoslahti E. (1998): Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest., 102, 430-437.
50. Ruoslahti E. and Rajotte D. (2000): An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol., 18, 813-827.
51. Saharinen P., Tammela T., Karkkainen M. J. and Alitalo K. (2004): Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol., 25, 387-395.
52. Schluesener H. J. and Xianglin T. (2004): Selection of recombinant phages binding to pathological endothelial and tumor cells of rat glioblastoma by in-vivo display. J. Neurol. Sci., 224, 77-82.
53. Sikes R. A., Nicholson B. E., Koeneman K. S., Edlund N. M., Bissonette E. A., Bradley M. J., Thalmann G. N., Cecchini M. G., Pienta K. J. and Chung L. W. (2004): Cellular interactions in the tropism of prostate cancer to bone. Int. J. Cancer, 110, 497-503.
54. Stacker S. A., Caesar C., Baldwin M. E., Thornton G. E., Williams R. A., Prevo R., Jackson D. G., Nishikawa S., Kubo H. and Achen M. G. (2001): VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med., 7, 186-191.
55. Viti F., Tarli L., Giovannoni L., Zardi L. and Neri D. (1999): Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res., 59, 347-352.
56. Wu H., Pancook J. D., Beuerlein G., Chilton T., Pecht G., Huse W. D. and Watkins J. D. (2002): Cloning, isolation and characterization of human tumor in situ monoclonal antibodies.Cancer Immunol. Immunother., 51, 79-90.
57. Zhu Z., Hattori K., Zhang H., Jimenez X., Ludwig D. L., Dias S., Russie P., Koo H., Kim H. J., Lu D., Liu M., Tejada R., Friedrich M., Bohlen P., Witte L. and Rafii S. (2003): Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia, 17, 604-611.
58. Zurita A. J., Arap W. and Pasqualini R. (2003): Mapping tumor vascular diversity by screening phage display libraries. J. Control Release, 91, 183-186.